Depomed Inc. appointed Phillip Donenberg as CFO and senior vice president, effective July 16.
Donenberg will succeed August Moretti, who has served as Depomed's CFO since January 2012.
Previously, Donenberg served as the CFO of AveXis Inc. and played a key role in the recent sale of AveXis to Novartis AG in an $8.7 billion deal.
Newark, Calif.-based Depomed is a specialty pharmaceutical company that engages in the development, sale and licensing of products for pain and other central nervous system conditions in the U.S.
